Evaluating only Dimension Therapeutics’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Product failure.
Key Events Timeline
FOUNDING
Founded in Cambridge, MA, by gene therapy pioneer Luk Vandenberghe to develop AAV liver-directed gene therapies.
FUNDING
Raised $100M in IPO on NASDAQ to advance hemophilia A and B gene therapy programs into clinical trials.
PRODUCT LAUNCH
DTX101 Phase 1/2 showed promising initial factor IX expression but levels declined due to immune clearance.
ACQUISITION ATTEMPT
Ultragenyx acquired Dimension for $152M before Phase 2 could definitively prove or disprove durability.
Full Analysis
Free · no account needed
Documented cause
Dimension Therapeutics developed AAV-based gene therapies for hemophilia A and B. Despite raising $100M in its 2015 IPO, Phase 1/2 results for DTX101 (hemophilia B) in 2016 showed transient efficacy with factor IX levels declining after initial elevation, suggesting immune response problems. Ultragenyx acquired Dimension for $152M in September 2017 before Phase 2 could prove clinical viability.
Lesson
“AAV gene therapy durability must be proven before IPO — transient results destroy long-term credibility.”